ArticleJournal of nanobiotechnology2026
Integration of bioinformatics analysis and experimental verification reveals the role of neutrophil extracellular traps in silica nanoparticles-induced lung injury.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSilica nanoparticles (SiNPs) are extensively produced and utilized, leading to regular human exposure in both living environmental and occupational settings. Numerous studies have confirmed the detrimental effects of SiNPs on respiratory health. Neutrophil extracellular traps (NETs), web-like networks of DNA, histones, and antimicrobial proteins that neutrophils release to trap and kill pathogens, are implicated in development of some acute and chronic lung diseases. Nevertheless, the specific role of NETs in the adverse pulmonary effects of SiNPs has not been described.
methodsMale C57BL/6 mice received intratracheal instillation of 80 nm SiNPs at 3.0 and 6.0 mg/kg body weight (bw), once weekly for 12 weeks, to simulate actual occupational exposure scenarios. Combined with bioinformatics analysis, this exploratory study investigated SiNPs-induced lung injury and the impact on metrics related to NETs. Subsequently, DNase I was used to explore the mitigating effect and mechanisms of promoting NETs degradation on SiNPs-induced lung injury. The DNase I was administered at a dose of 300 U per mouse via intraperitoneal injection, three times a week for 12 weeks.
resultsExposure to SiNPs induced pulmonary injury in C57BL/6 mice. Results of bioinformatic analyses and molecular bioassay techniques revealed that NETs, integrins αLβ2 and αMβ2, CD44, TGF-β and cytokines participate in SiNPs-induced lung injury. Targeted inhibition of NETs via DNase I attenuated the overexpression of integrins, CD44 and TGF-β, thereby mitigating SiNPs-induced lung injury.
conclusionExposure to SiNPs may cause pulmonary inflammation and fibrotic injury through NETs/integrins/TGF-β and NETs/cytokines/CD44 signaling pathways. Targeting NETs degradation may offer a novel therapeutic target for SiNPs-induced lung injury and provide a potential therapeutic avenue for inflammatory and fibrotic related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.